IL17A and myasthenia gravis: In CIA model, MG inhibits several inflammation-related ways such as NF-κB binding activity, NF-κB dependent expression of cytokines (TNF-α, IL-6, and IL-17), T and B lymphocytes, and macrophages in synovial cells.